Home › B-Cell Lymphoma › California
B-Cell Lymphoma clinical trials in California
20 studies for B-Cell Lymphoma are looking for participants at sites in California.
Cities in California
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Ucsf Fresno, Fresno
- Kaiser Permanente Southern California, Irvine
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06742996A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
- Providence Medical Foundation, Fullerton
- Cancer and Blood Specialty Clinic, Los Alamitos, Los Alamitos
- UCLA, Santa Monica
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07439653Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
- City of Hope Medical Center, Duarte
- City of Hope at Irvine Lennar, Irvine
RecruitingPhase 2
Ages 60 and older · All sexes · Updated Sep 25, 2026 · NCT06052826A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- City of Hope, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07101328Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Research Site, Duarte
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06526793A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- University of Southern California Norris Comprehensive, Los Angeles
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06634589Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
- City of Hope Comprehensive Cancer Center, Duarte
- University of California Davis Comprehensive Cancer Center, Sacramento
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT05272384A Study of ARC-02 in B-cell NHL
- Start Cala, Los Angeles
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT07691606Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- University of California-Irvine Medical Center, Irvine
- Cedars-Sinai Medical Center, Los Angeles
- University of California, Los Angeles (UCLA) Medical Center, Los Angeles
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT05826535A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- City of Hope, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06528301A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Pacific Cancer Medical Center, Inc, Anaheim
- TOI Clinical Research, Cerritos
- Stanford School of Medicine-Cancer Clinical Trials Office, Palo Alto
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05254743A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Cedars-Sinai Medical Center, Los Angeles
- University of California, Los Angeles (UCLA), Los Angeles
- University of California, Irvine, Orange
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- UC San Diego Health, La Jolla
- Stanford University, Stanford
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT04792489Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
- Stanford Medical Center, Stanford
RecruitingPhase 2
Ages 15 and older · All sexes · Updated May 27, 2026 · NCT06954805The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- City of Hope, Duarte
- Los Angeles Cancer Network, Los Angeles
- UCLA Medical Center of Hematology/Oncology, Los Angeles
- and 1 more
RecruitingPhase 1/2
Ages 12 to 95 · All sexes · Updated Apr 15, 2026 · NCT04329728Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 5, 2026 · NCT05801913Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 23, 2026 · NCT05432635BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
- City of Hope Medical Center, Duarte
- Stanford University, Stanford
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 20, 2025 · NCT05370430T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- University of California, Davis, Sacramento
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 7, 2025 · NCT06343311Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital Los Angeles, Los Angeles
- Children's Hospital Orange County, Orange
- UCSF School of Medicine, San Francisco
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Dec 6, 2024 · NCT05476770From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.